Detailed Notes on Recombinant
123). It truly is noteworthy that GLS2 is tumorigenic in breast cancer124, and its expression could compensate for lack of Gls in MYC-induced mouse liver tumours40. This suggests that GLS2 could confer resistance to GLS1-distinct inhibitors, including the allosteric inhibitor BPTES or CB-839, which resistance could be hypothetically avoided by the